News Release

Coronaviruses

Part 2

Book Announcement

Bentham Science Publishers

 

In this still pandemic period of SARS-CoV-2 (and its variants, especially ‘Delta’ variant) infection that is responsible for Covid-19, the scientific literature on these viruses and related cellular targets is crucial to help the researchers/virologists and clinicians from all countries to develop a new generation of safer and more effective vaccines, as well as treatments to cure the more or less severe diseases and damages to the many organs and tissues of SARS-Co--2-infected people. This second book on coronaviruses mainly brings together some useful information regarding the prevention/vaccination, and chemotherapies to the potential treatment of coronavirus infections. The collection combines eight chapters titled: (1) Broad spectrum antivirals to combat covid-19: The reality and challenges (chapter 1), (2) Covid-19: Preventive and protective control management strategies (chapter 2), (3) Plant-derived extracts and bioactive compounds against coronavirus progression: preventive effects, mechanistic aspects, and structures (chapter 3), (4) Gastroenteritis: symptoms and epidemiology of SARS-CoV-2 (chapter 4), (5) The chronicles of coronavirus: A Chinese king who conquered the entire world (chapter 5), (6) Traditional medicine as a natural remedy in ARDS & Covid-19 (chapter 6), (7) Molecular pathogenesis of human coronaviruses of 21st century (chapter 7), (8) COVID-19, mental health and neuropath physiology of pain related to temporomandibular disorder (chapter 8). Such a novel book compiling key data on SARS-CoV-2 and Covid-19 actually represents a tool of the utmost value for all researchers working on these research fields. It should also be of great interest to clinicians who are facing an overgrowing number of individuals with Covid-19. The data from 20th October 2021 give ca. 242 million cases of SARS-CoV-2 infection worldwide, with over 4.9 million deaths.

 

About the Editor:

Dr Jean-Marc Sabatier is a Director of research at the French CNRS, with Ph.D. and HDR degrees in Biochemistry and Microbiology. He headed several academic research teams (CNRS, INSERM, and University), as well as a combined academic-industry research laboratory devoted to the engineering of therapeutic peptides (ERT62, Marseilles, France). He was also a Director of Research for several French private companies as well as a Canadian public company. He acts as a Consultant for top pharmaceutical and cosmetic companies. Dr. Sabatier works in the field of animal toxins and microbes. He contributed to several books in toxinology and virology and more than 170 scientific articles, 180 communications, and 55 patents in both biology and chemistry. He is a member of 61 Editorial Boards of scientific journals, such as 'Peptides', 'Molecules', 'Antibiotics', and the 'Journal of Biological Chemistry'. He also reviewed articles submitted for publication in >100 international journals and acts as an expert for numerous national and international institutions. He won the 'Citizen of the Year Award' from the Nouvel Economiste (1994) for his work on antivirals. He is a member of a dozen scientific societies, such as the 'American Peptide Society' (charter member), 'European Peptide Society', 'American Society for Microbiology', 'Biochemical Society', and 'New-York Academy of Sciences'.

 

Keywords:

Virology, Medicinal Chemistry, Immunology, Pharmacology, SARS-CoV-2, Neutralizing antibody, Covid-19, Diagnostic, Herd Immunity, Vaccine, vacation, drug, Antiviral

 

For more information please visit https://bit.ly/3GYevNM


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.